NCT05107128Phase 2Completed

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-09-04Actual
Enrollment · participants189Actual
Source updated2025-09-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview